Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.81 |
| ▸ | USP2 | O75604 | 1/20 | 0.81 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.72 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.69 |
| ▸ | CDC25A | P30304 | 2/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18576366 | 1.00 | VDR (0.81) | VDRUSP2GPBAR1ST6GAL1CDC25A | |
| SCHEMBL18575846 | 0.90 | VDR (1.00) | VDRUSP2GPBAR1ST6GAL1ABCC4 | |
| SCHEMBL22855545 | 0.90 | VDR (1.00) | VDRUSP2GPBAR1ST6GAL1ABCC4 | |
| SCHEMBL678540 | 0.90 | VDR (1.00) | VDRUSP2GPBAR1ST6GAL1ABCC4 | |
| SCHEMBL18994243 | 0.90 | VDR (1.00) | VDRUSP2GPBAR1ST6GAL1ABCC4 | |
| SCHEMBL24897190 | 0.90 | VDR (1.00) | VDRUSP2GPBAR1ST6GAL1ABCC4 | |
| SCHEMBL11457420 | 0.90 | VDR (1.00) | VDRUSP2GPBAR1ST6GAL1ABCC4 | |
| SCHEMBL22871870 | 0.90 | VDR (1.00) | VDRUSP2GPBAR1ST6GAL1ABCC4 | |
| SCHEMBL18265875 | 0.90 | VDR (1.00) | VDRUSP2GPBAR1ST6GAL1ABCC4 | |
| SCHEMBL14360682 | 0.90 | VDR (1.00) | VDRUSP2GPBAR1ST6GAL1ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030482-B2 | 3-beta-tetrahydropyranyloxy-22-[4-(4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene-8-yl)butyroxy]-23-bisnorchol-5-ene, used in fluorescence spectroscopy for monitoring exchange, distribution and trafficking of cholesterol between living cells and lipid domains in membranes | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080177059-A1 | FREE CHOLESTEROL ANALOGS BEARING A BORON DIPYRROMETHENE DIFLUORO (BODIPY) FLUOROPHORE IN THE SIDE CHAIN AND METHOD OF PREPARATION AND USE THEREOF | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177059-A1 | FREE CHOLESTEROL ANALOGS BEARING A BORON DIPYRROMETHENE DIFLUORO (BODIPY) FLUOROPHORE IN THE SIDE CHAIN AND METHOD OF PREPARATION AND USE THEREOF | NPC1L1, CETP, NPC1 | VDR 973/4885USP2 3876/4885GPBAR1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.